Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership Expected to Accelerate...

TW's Take: Lantern continues to be on the leading edge of combining A.I. and oncology drug development. This partnership should help them not only...

Cash is King

After several weeks of lower stock prices, the market this past week decided that the looming bankruptcy of the world's largest real estate debt...

A September To Remember?

I read this week where someone said, "the short story is always sexier." There's certainly a lot of truth in that. Here in September...

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support...

TW's Take: Lantern is making all the right moves to set themselves up for long-term success. DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a...

FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma...

TW's Take: I feel like a broken record when I continually say that LP-184 is proving itself to be a highly potent molecule with...

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and...

TW's Take: more positive news on LP-184 which we believe has blockbuster potential. GBM is a serious disease with no treatment options for patients....

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation...

TW's Take: LP-184 is a compelling opportunity in multiple cancers. We continue to believe that Lantern is dramatically undervalued relative to the opportunities they...

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment...

TW's Take: more positive news backing development of LP-184, which is proving itself to be a potentially blockbuster drug with potential efficacy in many...

My Saturday Rant…

If you've been reading this newsletter for longer than two weeks, you likely have come to realize that I'm an investor not a trader....

Are We Having Fun Yet? Bull Ride Continues

The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles...

July About to Close With a Bang?

Last week wasn't a bad week for the markets at all. With a nice two day rally to end the week, the Russell 2000...

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

TW's Take: this is very positive pre-clinical data in a large disease with not many good treatment options. LP-184 is a potentially multi-billion dollar...

Kentucky Bluegrass

In a holiday shortened week, this newsletter comes from Kentucky where the TW household is attending a family wedding. Throw in a side journey...

Let’s Get Ready To Rumble (2nd Half Preview)

To steal a line from Charles Dickens, "It was the best of times. It was the worst of times. Then it was pretty darn...

Hoping for Fireworks

As the market seems to be slowly settling into summer, volatility is dropping and news flow is getting sparse. Amazing to think this is...

Stock Picking Wins This Week

It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market...

Reversal of Fortune

The pendulum had swung too far. Simply put, companies that are funded and executing on their gameplan cannot go down forever. Eventually they find...

Lantern Shines During Biotech Blackout

Biotech stocks continue to take it on the chin. This is the result of an overall shift from growth to value in the market...

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform...

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence...

TW's Take: this is very exciting news for Lantern as it is the first time they have licensed their RADR platform for third party...

Alpha-Bet Soup

There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion...

TW's Take: the rapid growth of datapoints on their A.I. platform is cementing Lantern (LTRN) as a leader in this field. A.I. is changing...

Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum...

TW's Take: our take is that LP-184 has the potential to be a billion dollar or more asset as it has shown potential potency...

The Lows Appear To Be In Place

Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested...

A Catalyst Filled Quarter Lies Around The Corner

My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...

Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor...

TW's Take: LP-184 is a very potent molecule. Combined with the resources of RADR, Lantern continues to find more potential treatments for the drug....

2nd Degree of Risk

Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at...

Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR...

TW's Take: "potentially best in class efficacy" sounds very good to us. LP-184 has great potential in many types of cancer. Lantern has a...

Sitting On My Hands

My Investment Style...It's Not For Everyone But It Works For Me I'm often asked why I don't trade more often. Many of my stocks make...

Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with...

TW's Take: the stereoisomer of LP-184, which has shown tremendous potential in many solid tumors, this new therapeutic also has many exciting potential uses...

Technically Speaking

I've always thought that technical analysts were like lawyers; you can always find one who will tell you what you want to hear. That said,...

Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights

TW's Take: 2021 is shaping up as an exciting year with many milestones on the calendar, the highlight of which will be multiple IND-enabling...

Blood In The Water

Good Morning Vietnam! Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...

When Will The Music Stop?

When you write a newsletter, being speechless is not a great place to be. However, what I'm seeing in the market right now leaves...

Next Up? INmune’s Big Week Finally Arrives

Frequently I hear from investors that something sounds, "too good to be true." And, being honest, more often than not, that's the case. But,...

Lantern Pharma Announces Pricing of $60 Million Public Offering

TW's Take: as usual, the biggest knock on this company was expectations of a financing. With this very large deal over, LTRN is now...

BOOM…Atomera Deal Highlights Another Bull Ride In The Market

Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on...

Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors...

TW's Take: we are very excited about this. ADC's are proving to be very effective and also companies focused on this space are in...

Put LP-184, a Potential Blockbuster in the Making, on Your Radar Screen

If you position yourself for success, sometimes you get lucky, right? It’s become common knowledge that A.I. is changing the way all companies do...

Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to...

TW's Take: Hopkins is the world leader in GBM. This announcement means that there are now three leading research institutes working with LP-184 on...

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug...

Tailwinds' Take: LP-184 is proving to be a very valuable drug for fighting multiple types of cancer, especially as a co-therapy with the standard...

The Micro-Cap Rally Continues Full Force

November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...

Lantern Pharma Earnings Call Transcript

Panna Sharma: Thank you Marek, and good afternoon to everyone on the call today. Thank you for joining us for our third quarter 2020 conference...

Sell Mortimer, Sell!!!

What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity...

Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress

Tailwinds' Take: crossing a billion datapoints is a big goal achieved ahead of schedule. The platform being developed by Lantern is getting more powerful...

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184,...

Tailwinds' Take: LP-184 has great potential as this collaboration with a leading research institute demonstrates. LTRN's unique AI capabilities have the potential to be...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

Wrapping Up A Chaotic Week

Markets were very volatile this past week, trading back and forth like a game of ping-pong. There's little doubt in my mind that the...

Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on...

Tailwinds' Take: LTRN will benefit greatly from this partnership through development of LP-184 and gobs more data for their machine learning process. This quote...

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Illuminating Lantern Pharma

Today we are initiating coverage of Lantern Pharma (LTRN). Lantern is a clinical stage biopharmaceutical company that uses artificial intelligence, advanced machine learning, genomics,...

Lantern Pharma Announces Upcoming Conference Presentations

DALLAS, Aug. 27, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") platform to transform the...

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

DALLAS, July 30, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.